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Abstract: 
 
Candida species are known to cause serious infections in immunocompromised patients but uncommon cases 
have been reported in immunocompetent individuals regardless of the harmless co-existence of the fungi with 
the host. Recently, the incidence rate of candidiasis has increased dramatically alongside the emergence of 
antifungal resistance. Although conventional methods to ensure prompt diagnosis of candidiasis for effective 
therapy have been established, the scientific world is witnessing progress in the development of more 
accurate, timely and cost-effective methods that is coinciding with the molecular revolution and advanced DNA 
analysis. Moreover, the challenges of resistance of Candida to available antifungal agents are being met with 
the deployment of molecular techniques to investigate the mechanisms of resistance. This review is an attempt 
to provide up-to-date information on the persistent problems of Candida with highlights on the clinical 
importance, molecular diagnosis, and resistance to candidate antifungal drugs; azoles and echinocandins.   
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Abstrait: 
 
Les espèces de Candida sont connues pour causer des infections graves chez les patients immunodéprimés, 
mais des cas peu communs ont été rapportés chez des individus immunocompétents, indépendamment de la 
coexistence inoffensive des champignons avec l'hôte. Récemment, le taux d’incidence de la candidose a 
considérablement augmenté parallèlement à l’émergence d’une résistance antifongique. Bien que les méthodes 
conventionnelles permettant d’assurer un diagnostic rapide de la candidose en vue d’un traitement efficace 
aient été établies, le monde scientifique constate des progrès dans la mise au point de méthodes plus précises, 
plus rapides et plus rentables qui coïncident avec la révolution moléculaire et l’analyse avancée de l’ADN. De 
plus, les défis posés par la résistance de Candida aux agents antifongiques disponibles sont résolus par le 
déploiement de techniques moléculaires pour étudier les mécanismes de résistance. Cette revue tente de 
fournir des informations à jour sur les problèmes persistants de Candida en soulignant l’importance clinique, le 
diagnostic moléculaire et la résistance aux antifongiques candidats; les azoles et les echinocandins. 
 




 The scientific term Candida was 
derived from the Latin name ‘candid’, 
referring to its white colour (1). Anton van 
Leeuwenhoek first observed yeast cells under 
the microscope  in 1680 (2) and classified it 
into kingdom Fungi, phylum Ascomycota, 
class Saccharomycetes, order Saccharo- 
mycetales, family Saccharomycetaceae and 
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genus Candida (3). The significant feature of 
yeast is the ability to alter its morphology 
from unicellular ovoid cells to pseudohyphae 
and hyphae forms. They are therefore known 
as dimorphic fungi (4). The morphological 
transition of yeast is stimulated by 
surrounding conditions such as temperature, 
pH, blood, serum and nutrient abundance 
(4). They form chlamydospores in specific 
conditions (5) and reproduce non-sexually by 
forming buds or sexually through mating (4).         
 Candida dwells in human body as a 
commensal where they are regarded as 
normal flora. They inhabit different body 
sites including the skin, mouth, gastro- 
intestinal tract and vagina,  and are generally 
harmless in immunocompetent individuals, 
scarcely infecting healthy people with only 
mild infections (6). However, they become 
pathogenic opportunistic fungi in individuals 




 During the period, September 2018 
to March 2019, we employed Google scholar 
engine to search for relevant published 
materials and bibliographic citations including 
original and review articles, books, and 
conference papers through the period 1985 
to 2018. Keywords employed for the search 
were Candidiasis, Candida diagnosis, Candida 
classification, Candida resistance, Candida 
molecular diagnosis, and Candida 
treatment. One hundred and ninety four 
reference materials were identified but 
following assessment of the relevance of the 
materials, only 70 reference materials were 
selected for the review.  
 
Clinical significance of Candida  
 
 Candida species of clinical importance 
include Candida albicans and non-albican 
Candida species such as Candida 
parapsilosis, Candida krusei, Candida 
glabrata, Candida dubliniensis, Candida 
tropicalis, Candida stellatoidea, Candida 
auris, Candida guilliermondii, Candida 
lusitaniae and Candida kyfer (8, 9). Clinically, 
C. albicans is of utmost significance because 
of its frequent isolation as a pathogenic and 
virulent species compared to other species 
(10). Genetically, C. albicans is diploid with 
heterozygous cells compared to C. glabrata 
that is haploid (10, 11) . C. albicans is also 
an imperfect yeast (vegetative) as its life 
cycle contains a non-sexual phase only (10).  
 Candida species can cause infections 
ranging from simple superficial to life 
threatening systemic diseases (12). 
Superficial infections affect the skin, nails 
and hair in addition to mucous layer (13) and 
include such diseases as athlete’s foot, ring 
worm, oral and vaginal thrush (14,15). 
Studies have shown that approximately 75% 
of females suffer from vaginal Candida 
infections (vulvovaginal candidiasis) at least 
once during their life (16). Candida has been 
reported as the third or fourth cause of 
nosocomial infections in the United States 
(17) and as an insidious pathogen causing 
ocular candidiasis, cerebral candidiasis or 
candida meningitis in infants and susceptible 
adults (8).     
 Shetti and co-workers reported for 
the first time in 2011 that Candida treatment 
failure is an indicator of HIV infection (18). 
Similar to other pathogenic agents, 
opportunistic pathogenic Candida species 
possess virulence factors that enable 
colonization and host infection. The stages of 
infection involve inoculation, adherence to 
the host tissue, penetration and 
dissemination to other body sites through the 
bloodstream (6).     
      
Risk factors for Candida infection 
 Candida infections are associated 
with multiple risk factors and the prevalence 
of Candida infection is related to the ability of 
the pathogen to adapt to environmental 
factors, for example, pathogenic species 
successfully grow and multiply at 37oC 
compared to non-pathogenic species (8,13). 
The risk factors can be categorized into two; 
(i) factors associated with medical 
management and (ii) factors related to host 
immune status.   
 Recent advances in health care 
management and medications have provided 
the opportunity of a suitable environment 
that supports Candida growth and 
colonisation of the host. Such factors include 
catheterization, parentheral nutrition, organ 
transplantation, prolonged hospitalization, 
and use of new medications (8). On the other 
hand, host factors such as age, gender, and 
immune status determine the incidence of 
candidiasis (8).    
 An invitro study showed that nicotine 
concentrations of cigarette smoke are 
associated with yeast growth and adherence 
in both biofilm and plankton forms (19). 
Others have shown an association between 
Candida infections and iron deficiency, owing 
to the relationship of iron and the strength of 
the immune system (20). Newborns are at 
risk of infection with Candida species because 
of the risk of transmission from the mother 
during childbirth and perinatal period (21). 
Moreover, patients with AIDS, oral cancer, 
cystic fibrosis, dentures, and recipients of 
lung, liver, stem cell or other solid organs are 
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highly susceptible to Candida infections (6, 
22) 
Laboratory diagnosis of Candidiasis 
 The accurate diagnosis of infection 
caused by pathogenic microorganisms is an 
important guide in the selection of 
appropriate treatment regimen (23). The 
diagnosis of fungi infection is complex due to 
overlapping symptoms and signs with other 
infections, patients’ age, health status and 
environmental factors (24). Advances in the 
field of mycology have led to the 
development of diagnostic methods for fungi 
infections (1). Two mycological laboratory 
approaches are employed in the diagnosis of 
Candida infections; conventional standard 
(microscopy and culture) and non-culture 
methods such as serology and molecular 
techniques (25) (Fig 1).   
 In the era of molecular diagnosis, 
new techniques have been developed and 
used for accurate identification of fungi (26). 
However, the conventional methods are still 
employed in combination with the new 
advanced molecular techniques (27). As 
explained by Kurtzman et al., the 
conventional methods are necessary for the 
understanding of the fungi and their 
ecological interactions in addition to 
obtaining accurate results through molecular 
analysis of their gene variations and 
modifications (28).  
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Molecular identification of Candida 
Polymerase chain reaction (PCR) assay          
 PCR technique is useful for basic 
molecular identification of the organism, 
however successful PCR depends on DNA 
extraction, purity and quantity (29). The 
amplification by PCR involves three phases of 
denaturation, annealing (hybridization) and 
extension. To amplify specific target DNA 
sequence in a conventional PCR, specific 
primers are designed to hybridize to the 
sequence of target and amplification carried 
out in master mix PCR reaction tubes inside a 
thermal cycler machine. PCR products are 
then separated on an agarose gel to visualize 
the DNA bands and confirm successful DNA 
fragment amplification (29).   
 PCR techniques are promising assays 
that evaluate and differentiate yeast and 
pathogenic fungi species. In particular, the 
multiplex PCR is a simple, timely and cost 
effective approach to identify different 
species of yeasts (30). Luo et al., skipped the 
DNA extraction step and amplified DNA 
directly from the yeast colony. This 
modification reduced the turn-around-time 
for the assay and avoided the obstacle of 
DNA isolation which reduced the overall cost 
(30).      
 The conserved sequences in the 
genome of organisms exhibit divergence 
among different species, the knowledge of 
these variations have been utilized to 
determine relatedness between species (26). 
Kurtzman and Robnett investigated the 
relatedness between yeast species using the 
variations of D1/D2 domain in a large subunit 
(26S) of ribosomal DNA, while at the same 
time, amplifying and sequencing the Internal 
Transcribed Spacer (ITS) region with 
universal primers, and comparing this with 
the BLAST database (31,32).   
 There are two ITS regions, which are 
non-coding regions located between the 
small and large subunits of rRNA. In fungi, 
ITS1 and ITS2 are located in the rDNA gene 
complex between the 18s and 5.8s rRNA and 
5.8s and 26s rRNA genes respectively (32). 
These regions are distinguished by their 
variations among fungal species and have 
therefore been selected as DNA barcode to 
differentiate the fungal species (33). Leaw et 
al., have demonstrated the candidate ITS 
regions for Candida species identification. 
First, the length of the amplified ITS 
fragments differs among Candida species 
(34). However, the maximum length (size) of 
the DNA fragment amplified is less than 0.3 
kb, with the exception of Saccharomyces 
cerevisiae with length of 3.7 kb and C. 
glabrata with 0.4 kb (34). Secondly, the 
identification of yeast species, depending on 
the ITS regions (particularly ITS2) is reliable, 
accurate and timely (it can be completed 
within 24 hours) when used in identification 
of clinical isolates (34). Romeo et al. (35) 
used specific primers targeting the HWP1 
gene to differentiate between C. albicans, C. 
africana and C. dubliniensis by amplifying 
different sizes of DNA segments with sizes of 
941 bp, 700 bp and 569 bp respectively (35).  
Random amplified polymorphic DNA               
 The amplification of random 
fragments of genomic DNA to investigate 
genetic diversity among species is called 
random amplified polymorphic DNA (RAPD) 
and it has been used to study the relatedness 
of Candida isolates (36). The advantages of 
the RAPD assay is that of simplicity with no 
need for precise DNA sequence data, rapidity 
and lower cost. However, the problem of 
reproducibility is a major disadvantage 
because non-specific or arbitrary primers 
annealed to the DNA under demanding 
conditions (37,38). The study by Valério et al 
reported that RAPD may be unreliable due to 
the phenotypic switching in Candida species 
(39).  
Pulsed-field gel electrophoresis assay 
 The investigation of the karyotypes of 
Candida species is an additional means of 
differentiating between Candida species 
which can be achieved with pulsed-field gel 
electrophoresis (PFGE) assay (38). However, 
this analytical assay is time consuming and 
labour intensive. 
 
Nucleic acid sequence based amplification 
 Nucleic acid sequence based ampli- 
fication (NASBA) is an alternative method to 
PCR technique that is used to amplify specific 
segments of rRNA using RNA polymerase to 
detect active pathogens (40). 
 
Restriction fragment length polymorphism  
 The polymerase chain reaction-
restriction fragment length polymorphism 
(PCR-RFLP) technique has contributed to the 
precise diagnosis of Candida species. Mousavi 
et al., identified five Candida species; C. 
albicans, C. krusei, C. glabrata, C. tropicalis 
and C. guilliermondii by PCR-RFLP technique 
(41). The technique involves amplification of 
DNA segments using universal primers ITS1 
and ITS4, followed by digestion of the 
amplified products using Msp I restriction 
enzyme (41). The digested products are 
separated on agarose gel and the 
characteristic band patterns are interpreted 
according to established protocol. 
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Table 1: Summary of the targets and actions of antifungal agents (44) 





Targets the integrity of the cell membrane by binding to ergosterol, owing 
to its affinity to ergosterol more than any other sterol. The drug affects 
permeability by forming pores in the cell membrane. 
Azole Cell membrane 
(ergosterol) 
Targets the synthesis of ergosterol by inhibiting lanosterol 14-alpha-
demethylase, which converts lanosterol to ergosterol in the fungal cell 
membrane. 
Echinocandin Cell wall 
(glucan) 
Targets the integrity of the fungal cell wall by inhibiting B-glucan synthase, 
leading to the inhibition of glucan synthesis. 
Flucytosine DNA and RNA 
synthesis 
5-Flucytosin uptake is undertaken by the cytosine permease and this 
interferes with the pathways used for DNA and RNA synthesis. 
 
Candida treatment and resistance 
 Four major classes of anti-fungal 
agents are approved by the United States 
Food and Drug Administration (FDA); 
amphotericin, azole, ecchinocandin and 
flucytosine (42). The mechanism of action of 
each class is summarised in Table 1. 
Compared to the wide range of antibacterial 
drugs, only a few antifungal drugs are 
available with noticeable side effects due to 
the similarity of fungal and human cell 
membrane (both are eukaryotic cells) which 
is the site of action of a large number of 
antifungal agents (43). Echinocandins and 
azoles are the most effective antifungal 
agents against candidiasis. Echinocandins 
tend to have fewer side effects than other 
antifungal classes due to the absence of a 
cell wall (its target of action) in the human 
cell (43).                                                         
 In spite of the success of these 
classes of anti-fungals for treatment of yeast 
and mould infections, these fungal pathogens 
have developed resistance to these drugs 
(44). Resistance to anti-fungal agents occur 
through mutational changes in the genome of 
the fungi leading to modifications of the 
metabolic pathway of the drugs in the 
pathogen (44). There are two categories of 
resistance; primary (intrinsic) and secondary 
(acquired). Primary resistance is genetically 
inherited from the parent as seen in human 
pathogenic fungi such as Lomentospora 
prolificans, which is intrinsically resistant to 
all antifungal drugs (45). Secondary 
resistance is acquired from surrounding 
environment (46). 
Molecular mechanisms of drug 
resistance in Candida 
 In more recent years, the 
determination of genes and their product 
functions have been carried out via molecular 
and genetic engineering techniques, such as 
through the determination of the gene 
mutations which cause clinical failure through 
gene sequencing or tracking gene expression 
using real time PCR or microarrays (47,48). 
Candida species have developed various 
mechanisms to resist antifungal medications 
depending on the type of drugs, mechanisms 
of action and drug targets (44). The most 
commonly available antifungal drugs for 
treatment of candidiasis are azoles and 
echinocandins but Candida species have 
developed resistance to them (49).  
Resistance to echinocandins 
 Echinocandin inhibits the enzyme, β-
1,3-D-glucan synthase, leading to arrest in 
the biosynthesis of β-1,3-D glucan and 
disruption of the integrity of the fungal cell 
wall (43) (Table1). The enzyme is composed 
of two subunits; catalytic ‘Fks’ subunit and 
regulatory ‘Rho’ subunit though echinocandin 
targets the Fks1 gene (43).  
 Candida species have developed 
resistance to echinocandin despite its 
effectiveness. The exposure of C. albicans to 
echinocandin induces the synthesis of chitin 
(50). Two signalling pathways; PKC Ca2+-
calcineurin and HOG, regulate the expression 
of the genes for chitin synthesis (51). Both 
signalling pathways are involved in the 
activation of transcriptional stimulation        
in response to echinocandins (50).
 Additionally, presence of mutations in 
the Fks1 gene is associated with resistance 
to echinocandin. For example, sequencing of 
resistant C. auris isolates showed subs- 
titution of serine to phenylalanine in the Fks1 
gene locus (9). Mutations in the conserved 
region of the Fks1 gene are called ‘hot spots’ 
for acquisition of Candida resistance to 
ecchinocandin (52). 
Resistance to azoles    
 Azole targets ergosterol biosynthesis 
(Table 1) but Candida has developed four 
mechanisms to circumvent the fungicidal 
mechanism of azole including an efflux pump 
to lower drug concentration within the cell, 
modification of the ergosterol target, 
elevating levels of  production of the targeted 
enzyme, and the establishment of alternative 
pathways (44). Some strains showed cross  
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resistance to antifungal drugs. C. tropicalis 
carried more than one mutations leading to 
azole-polyene cross resistance (53). 
 Two types of transporter proteins, 
which export different elements such as 
carbohydrate include the ATP-binding 
cassette (ABC) and the major facilitator 
superfamily (MFS) (54). These proteins are 
encoded by the CDR and MDR genes 
respectively. The efflux pump encoding 
genes; FLR1, AZR1 and TPO1 are associated 
with resistance to flucytosine, ketoconazole 
and caspofungin respectively (55,56,57). 
Studies have shown that Candida utilised 
these genes to expel drugs taken by the cell 
outside of the cells thereby reducing the 
concentration within the cell to ineffective 
level (54). The upregulation of transporter 
genes is thus associated with azole 
resistance in C. albicans (58).   
 The transcriptional profiling of 
resistant C. glabrata isolates to azole has 
been compared with their counterpart 
susceptible isolates using DNA microarray 
technique. The results showed that the 
upregulation of PDR1 genes (related to a 
single mutation in a different locus of 
CgPDR1 ORF) is associated with azole 
resistance (59). Northern blot analysis 
revealed that CDR1, CDR2 and MDR1 genes 
were over-expressed in the resistance 
isolates compared to susceptible strains (60). 
The disruption of single or double genes 
involved in the efflux pump generated 
mutants sensitive to fluconazole rather than 
the resistance parent strains in the plankton 
(61).      
 Another mechanism in which the 
Candida species develop resistance to azole 
antifungal drugs is by modifying the drug 
targets (62). ERG11 gene encodes lanosterol, 
14-α-demethylase (Erg11p), which is tar- 
geted by the azole antifungal drug (62). The 
analysis of PCR products (products mediated 
by gene amplification from sensitive and 
resistance strains) was used to investigate 
point mutations of the CYP51 gene in the 
resistance isolates that reduced the function 
of azole (63). Point mutation leads to amino 
acid substitution leading to decreased binding 
of the azole to its target. Flowers et al., 
characterised 26 novel point mutations while 
Morio et al., highlighted more than 140 
mutations leading to amino acid 
substitutions. Mutations in the genome 
sequence, involving ERG3 and ERG11 genes 
of C. tropicalis, led to development of 
resistance to azoles (53).   
 The action of azole against the fungal 
cells interferes with the synthesis of 
functional ergosterol and produces a toxic 
intermediate compound called 14α methyl-
3.6-diol, blocking fungi growth (44). 
However, Candida species have developed 
another mechanism to resist azole drugs by 
establishing an alternative pathway. For 
instance, a missense mutation in the  
ERG3 gene of C. tropicalis leads to 
accumulation of the sterol intermediates, 
ergosta-7,22-dienol and ergosta-7-enol 
instead of ergosterol (64). C. albicans strains 
produce functional sterol 14α-methyl- 
fecosterol instead of ergosterol, which leads 
to development of resistance to fluconazole 
(65). Another study reported that reduction 
of C. krusei susceptibility to azole drugs was 
related to up-regulation of Erg11p expression 
(66). The overexpression of the ERG11 gene 
is associated with the mutation of the UPC2 
gene (zinc cluster transcription factor) (68). 
In a study that targeted the UPC2 gene 
disruption, there was reduction in ERG11 
expression in the UPC2 deficient mutant 
compared to wild type strains (67). It was 
shown that the mutation in the UPC2 gene 
coinciding with the upregulation of Erg11 
expression was one of the mechanisms of 
increase, causing ERG11 gene over- 
expression. However, other mechanisms do 
exist (69). 
Conclusion: 
 Candida species cause a wide range 
of infections from mild to severe life 
threatening diseases. Meanwhile, they inhabit 
the human body as normal flora. It could 
therefore be said that these normal flora are 
silent enemies because they exploit 
opportunities and attack the body in the 
event of a perturbation of the immune 
system. Apart from this, Candida species 
have the ability to modify their genome to 
develop resistance to antifungal drugs. 
Although, azoles and ecchinocandins are the 
most common antifungal agents effective 
against Candida infections, resistance to 
these drugs are increasing.   
 In recent time, attempts have been 
made to develop methods of identifying 
Candida species by exploring certain 
variations in the conserved region of their 
genome to determine relatedness between 
species. To solve the problem of increasing 
resistance to antifungal agents, molecular 
techniques are being utilized to investigate 
gene modifications that overcome the action 
of antifungal drugs. These efforts aspire to 
develop more accurate, effective and less 
time-consuming methods of diagnosis in 
addition to developing new antifungal agents. 
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